Brookstone Capital Management Makes New $1.48 Million Investment in United Therapeutics Corporation (NASDAQ:UTHR)

Brookstone Capital Management bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,798 shares of the biotechnology company's stock, valued at approximately $1,479,000.

A number of other institutional investors also recently modified their holdings of UTHR. Cerity Partners LLC lifted its stake in shares of United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after purchasing an additional 2,702 shares during the period. Korea Investment CORP lifted its stake in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after purchasing an additional 2,300 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the last quarter. Nepsis Inc. lifted its holdings in shares of United Therapeutics by 6.7% during the first quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock valued at $18,057,000 after purchasing an additional 3,653 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in shares of United Therapeutics during the fourth quarter valued at approximately $1,899,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. UBS Group reduced their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Bank of America reduced their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $386.15.

United Therapeutics Stock Performance

Shares of UTHR traded down $4.10 during midday trading on Monday, hitting $290.39. 649,708 shares of the company traded hands, compared to its average volume of 446,457. The firm has a 50 day moving average of $301.21 and a 200-day moving average of $322.02. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The stock has a market cap of $13.10 billion, a price-to-earnings ratio of 11.59, a PEG ratio of 6.45 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter last year, the firm earned $6.17 EPS. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $10,297,208.76. This represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the sale, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. The trade was a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,681 shares of company stock worth $22,813,739 in the last quarter. Company insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.